These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29801053)

  • 61. Spinal muscular atrophy: Further expanding the clinician's armamentarium.
    Brandsema JF; Sumner CJ
    Neurology; 2019 Oct; 93(14):613-614. PubMed ID: 31488614
    [No Abstract]   [Full Text] [Related]  

  • 62. Spinal muscular atrophy: A preliminary result toward new therapy.
    Nevo Y; Wang C
    Neurology; 2016 Mar; 86(10):884-5. PubMed ID: 26865521
    [No Abstract]   [Full Text] [Related]  

  • 63. Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.
    La Foresta S; Faraone C; Sframeli M; Vita GL; Russo M; Profazio C; Rulli I; Gitto E; Versaci A; Messina S; Vita G
    Neurol Sci; 2018 Nov; 39(11):1961-1964. PubMed ID: 30043247
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.
    Arnold W; McGovern VL; Sanchez B; Li J; Corlett KM; Kolb SJ; Rutkove SB; Burghes AH
    Neurobiol Dis; 2016 Mar; 87():116-23. PubMed ID: 26733414
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Spinal muscular atrophy: A modifiable disease emerges.
    Fitzgerald DA; Abel F; Jones KJ; Farrar MA
    Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
    [No Abstract]   [Full Text] [Related]  

  • 66. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
    Jecker NS
    Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
    [No Abstract]   [Full Text] [Related]  

  • 67. Rewriting the (tran)script: Application to spinal muscular atrophy.
    Ratni H; Mueller L; Ebeling M
    Prog Med Chem; 2019; 58():119-156. PubMed ID: 30879473
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Spinal muscular atrophy 5Q - Treatment with nusinersen.
    ; Silvinato A; Bernardo WM
    Rev Assoc Med Bras (1992); 2018 Jun; 64(6):484-491. PubMed ID: 30304304
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New treatments for serious conditions: ethical implications.
    King NMP; Bishop CE
    Gene Ther; 2017 Sep; 24(9):534-538. PubMed ID: 28467402
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
    Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.
    Shorrock HK; Gillingwater TH; Groen EJN
    Drugs; 2018 Mar; 78(3):293-305. PubMed ID: 29380287
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gene therapy rescues newborns with spinal muscular atrophy.
    Sheridan C
    Nat Biotechnol; 2018 Aug; 36(8):669-670. PubMed ID: 30080825
    [No Abstract]   [Full Text] [Related]  

  • 73. Making sense of antisense oligonucleotides: A narrative review.
    Goyal N; Narayanaswami P
    Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic advances in 5q-linked spinal muscular atrophy.
    Reed UC; Zanoteli E
    Arq Neuropsiquiatr; 2018 Apr; 76(4):265-272. PubMed ID: 29742241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treating Disease at the RNA Level with Oligonucleotides.
    Levin AA
    N Engl J Med; 2019 Jan; 380(1):57-70. PubMed ID: 30601736
    [No Abstract]   [Full Text] [Related]  

  • 76. Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: a variant of infantile spinal muscular atrophy.
    Bertini E; Gadisseux JL; Palmieri G; Ricci E; Di Capua M; Ferriere G; Lyon G
    Am J Med Genet; 1989 Jul; 33(3):328-35. PubMed ID: 2801766
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spinal muscular atrophy approval boosts antisense drugs.
    Dolgin E
    Nat Biotechnol; 2017 Feb; 35(2):99-100. PubMed ID: 28178250
    [No Abstract]   [Full Text] [Related]  

  • 78. [On the problem of spinal muscular atrophy resembling progressive muscular dystrophy (Kugelberg-Welander's juvenile muscular atrophy)].
    GOLDSZTAJN M; ZEBROWSKI S
    Neurol Neurochir Psychiatr Pol; 1962; 12():669-73. PubMed ID: 13948828
    [No Abstract]   [Full Text] [Related]  

  • 79. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Innovative therapeutic approaches for hereditary neuromuscular diseases].
    Kirschner J; Schoser B
    Nervenarzt; 2018 Oct; 89(10):1115-1122. PubMed ID: 30171303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.